Exicure Inc
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Exicure Inc (XCUR) - Net Assets
Latest net assets as of September 2025: $6.93 Million USD
Based on the latest financial reports, Exicure Inc (XCUR) has net assets worth $6.93 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.27 Million) and total liabilities ($8.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.93 Million |
| % of Total Assets | 45.37% |
| Annual Growth Rate | -10.42% |
| 5-Year Change | -88.99% |
| 10-Year Change | N/A |
| Growth Volatility | 245.71 |
Exicure Inc - Net Assets Trend (2015–2024)
This chart illustrates how Exicure Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Exicure Inc (2015–2024)
The table below shows the annual net assets of Exicure Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.77 Million | +123.42% |
| 2023-12-31 | $3.03 Million | -79.69% |
| 2022-12-31 | $14.92 Million | +32.85% |
| 2021-12-31 | $11.23 Million | -81.74% |
| 2020-12-31 | $61.51 Million | -23.83% |
| 2019-12-31 | $80.75 Million | +285.39% |
| 2018-12-31 | $20.95 Million | +4.89% |
| 2017-12-31 | $19.98 Million | +715.97% |
| 2016-12-31 | $2.45 Million | -86.57% |
| 2015-12-31 | $18.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Exicure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19360100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.01% |
| Other Components | $206.03 Million | 3042.45% |
| Total Equity | $6.77 Million | 100.00% |
Exicure Inc Competitors by Market Cap
The table below lists competitors of Exicure Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asia Economy Daily Co Ltd
KQ:127710
|
$15.37 Million |
|
Gold Hydrogen Ltd
AU:GHY
|
$15.37 Million |
|
South Pacific Metals Corp
PINK:SPMEF
|
$15.37 Million |
|
Fortifai Ltd
AU:FTI
|
$15.37 Million |
|
Multi Spunindo Jaya Tbk.
JK:MSJA
|
$15.36 Million |
|
Wilton Makmur Indonesia Tbk
JK:SQMI
|
$15.35 Million |
|
Atlas Pearls Ltd
OTCMKTS:APCFF
|
$15.35 Million |
|
ERSU Meyve ve Gida Sanayi AS
IS:ERSU
|
$15.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Exicure Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,031,000 to 6,772,000, a change of 3,741,000 (123.4%).
- Net loss of 9,701,000 reduced equity.
- New share issuances of 12,402,000 increased equity.
- Other factors increased equity by 1,040,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.70 Million | -143.25% |
| Share Issuances | $12.40 Million | +183.14% |
| Other Changes | $1.04 Million | +15.36% |
| Total Change | $- | 123.42% |
Book Value vs Market Value Analysis
This analysis compares Exicure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.33x to 4.09x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $13.92 | $4.54 | x |
| 2016-12-31 | $1.86 | $4.54 | x |
| 2017-12-31 | $15.19 | $4.54 | x |
| 2018-12-31 | $15.26 | $4.54 | x |
| 2019-12-31 | $42.00 | $4.54 | x |
| 2020-12-31 | $21.16 | $4.54 | x |
| 2021-12-31 | $3.80 | $4.54 | x |
| 2022-12-31 | $3.23 | $4.54 | x |
| 2023-12-31 | $0.38 | $4.54 | x |
| 2024-12-31 | $1.11 | $4.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Exicure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -143.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1940.20%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.22x
- Recent ROE (-143.25%) is above the historical average (-228.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -72.14% | -550.71% | 0.12x | 1.08x | $-14.97 Million |
| 2016 | -692.03% | -1635.23% | 0.05x | 8.41x | $-17.19 Million |
| 2017 | -55.12% | -113.29% | 0.34x | 1.45x | $-13.01 Million |
| 2018 | -106.97% | -18994.07% | 0.00x | 1.37x | $-24.51 Million |
| 2019 | -32.57% | -2029.55% | 0.01x | 1.43x | $-34.38 Million |
| 2020 | -40.11% | -148.49% | 0.17x | 1.63x | $-30.82 Million |
| 2021 | -570.71% | 0.00% | -0.01x | 5.78x | $-65.23 Million |
| 2022 | -17.30% | -8.96% | 1.24x | 1.56x | $-4.07 Million |
| 2023 | -558.03% | 0.00% | 0.00x | 3.82x | $-17.22 Million |
| 2024 | -143.25% | -1940.20% | 0.03x | 2.22x | $-10.38 Million |
Industry Comparison
This section compares Exicure Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Exicure Inc (XCUR) | $6.93 Million | -72.14% | 1.20x | $15.36 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |